Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

A meta-analysis of the prognostic impact of tissue golgi protein 73 (tGP73) in hepatocellular carcinoma

Authors: Wei-Ming Yu, Guo-Wei Li, Ming-Geng Lou, Zheng-Yu Wu

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Introduction

To date, an increasing number of studies have revealed that GP73 may have prognostic value in liver cancer. However, most of the studies evaluated serum GP73, and the results regarding the prognostic value of tGP73 in liver cancer are still controversial. Therefore, in this meta-analysis, we aimed to determine whether tGP73 has any prognostic value in patients with HCC.

Materials and methods

Relevant publications were searched for in PubMed, EMBASE, OVID, the Cochrane Library, and the Web of Science databases up to March 2023. The hazard ratio (HR) or odds ratio (OR) with corresponding 95% confidence intervals (95% CIs) of eligible studies were assessed by fixed-effects or random-effects models. In addition, subgroup analyses were conducted to investigate the possible causes of heterogeneity, and publication bias analysis was also performed to assess the reliability of the meta-analysis results.

Results

A total of 10 studies were included. These studies included 1569 HCC patients, and a meta-analysis was performed. The results of our meta-analysis showed that higher GP73 expression levels were significantly associated with poorer OS (HR = 1.87, 95% CI: 1.41–2.48, P < 0.0001, I2 = 58%). However, there was no significant correlation between high GP73 expression and disease-free survival (DFS) (HR: 1.43, 95% CI: 0.93–2.33, P = 0.100). In addition, abnormal GP73 expression was also related to higher tumour tissue differentiation grade (OR = 3.03, 95% CI = 2.01–4.57, P < 0.0001, I2 = 89%), later tumour stage (OR = 5.89, 95% CI = 2.31–14.99, P < 0.0001, I2 = 0%), vascular invasion (OR = 1.72, 95% CI = 1.12–2.64, P = 0.010, I2 = 0%), multiple tumours (OR = 2.44, 95% CI = 1.37–3.68, P = 0.001, I2 = 44%) and early postoperative tumour recurrence (OR = 1.92, 95% CI = 1.10–3.28, P = 0.020, I2 = 62%).

Conclusions

The meta-analysis showed that the overexpression of GP73 may be related to a poor prognosis of HCC, and it may also have a predictive effect on the invasion and metastasis of HCC.
Literature
1.
go back to reference Nabih HK. The significance of HCV viral load in the incidence of HCC: a correlation between Mir-122 and CCL2. J Gastrointest cancer. 2020;51(2):412–7.CrossRefPubMed Nabih HK. The significance of HCV viral load in the incidence of HCC: a correlation between Mir-122 and CCL2. J Gastrointest cancer. 2020;51(2):412–7.CrossRefPubMed
2.
go back to reference Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Reviews Gastroenterol Hepatol. 2019;16(10):589–604.CrossRef Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Reviews Gastroenterol Hepatol. 2019;16(10):589–604.CrossRef
3.
go back to reference Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, Layese R, Costentin C, Cagnot C, Durand-Zaleski I, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in France and in the United States. Hepatology. 2017;65(4):1237–48.CrossRefPubMed Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, Layese R, Costentin C, Cagnot C, Durand-Zaleski I, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in France and in the United States. Hepatology. 2017;65(4):1237–48.CrossRefPubMed
4.
go back to reference Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141(2):526–35. 535.e521-522.CrossRefPubMed Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology. 2011;141(2):526–35. 535.e521-522.CrossRefPubMed
5.
go back to reference Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Reviews Clin Oncol. 2018;15(10):599–616.CrossRef Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Reviews Clin Oncol. 2018;15(10):599–616.CrossRef
6.
go back to reference El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.CrossRefPubMedPubMedCentral El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.CrossRefPubMedPubMedCentral
7.
8.
go back to reference Bao YX, Cao Q, Yang Y, Mao R, Xiao L, Zhang H, Zhao HR, Wen H. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol. 2013;8:197.CrossRefPubMedPubMedCentral Bao YX, Cao Q, Yang Y, Mao R, Xiao L, Zhang H, Zhao HR, Wen H. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn Pathol. 2013;8:197.CrossRefPubMedPubMedCentral
9.
go back to reference Dai T, Zhang D, Cai M, Wang C, Wu Z, Ying Z, Wu J, Li M, Xie D, Li J, et al. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway. J Pathol. 2015;235(3):490–501.CrossRefPubMed Dai T, Zhang D, Cai M, Wang C, Wu Z, Ying Z, Wu J, Li M, Xie D, Li J, et al. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-κB pathway. J Pathol. 2015;235(3):490–501.CrossRefPubMed
10.
go back to reference Jiang K, Li W, Shang S, Sun L, Guo K, Zhang S, Liu Y. Aberrant expression of Golgi protein 73 is indicative of a poor outcome in hepatocellular carcinoma. Oncol Rep. 2016;35(4):2141–50.CrossRefPubMed Jiang K, Li W, Shang S, Sun L, Guo K, Zhang S, Liu Y. Aberrant expression of Golgi protein 73 is indicative of a poor outcome in hepatocellular carcinoma. Oncol Rep. 2016;35(4):2141–50.CrossRefPubMed
11.
go back to reference Yang H, Xu H, Wang Y, Zhang J, Sang X, Mao Y. Clinicopathologic correlations of Golgi protein 73 and signal transducer and activator of transcription 3 expression in hepatocellular carcinoma. Translational Cancer Research. 2017;6(1):238–46.CrossRef Yang H, Xu H, Wang Y, Zhang J, Sang X, Mao Y. Clinicopathologic correlations of Golgi protein 73 and signal transducer and activator of transcription 3 expression in hepatocellular carcinoma. Translational Cancer Research. 2017;6(1):238–46.CrossRef
12.
go back to reference Mao Y, Yang H, Sun L, Mao Y, Qin X. Upregulated GP73 expression and downregulated NLRP3 expression in Liver cancer tissues correlate with patient’s survival. Translational Cancer Research. 2018;7(2):441–9.CrossRef Mao Y, Yang H, Sun L, Mao Y, Qin X. Upregulated GP73 expression and downregulated NLRP3 expression in Liver cancer tissues correlate with patient’s survival. Translational Cancer Research. 2018;7(2):441–9.CrossRef
13.
go back to reference Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, Lei HJ, Hsiao M, Huang SF, Huang CY, Chau GY. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Ann Surg Oncol. 2013;20(Suppl 3):616–24.CrossRef Chen MH, Jan YH, Chang PM, Chuang YJ, Yeh YC, Lei HJ, Hsiao M, Huang SF, Huang CY, Chau GY. Expression of GOLM1 correlates with prognosis in human hepatocellular carcinoma. Ann Surg Oncol. 2013;20(Suppl 3):616–24.CrossRef
14.
go back to reference Shan SG, Gao YT, Xu YJ, Huang Y, Zhang Q, Zhai DK, Li JB, Wang FM, Jing X, Du Z, et al. Gradually increased Golgi protein 73 expression in the progression of benign Liver Diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients. Hepatol Research: Official J Japan Soc Hepatol. 2013;43(11):1199–210.CrossRef Shan SG, Gao YT, Xu YJ, Huang Y, Zhang Q, Zhai DK, Li JB, Wang FM, Jing X, Du Z, et al. Gradually increased Golgi protein 73 expression in the progression of benign Liver Diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients. Hepatol Research: Official J Japan Soc Hepatol. 2013;43(11):1199–210.CrossRef
15.
go back to reference Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. A meta-analysis of the prognostic significance of Golgi protein 73 in hepatocellular carcinoma in Chinese patients. Archives of Medical Science: AMS. 2020;16(5):1104–10.CrossRefPubMed Zhang J, Zhang M, Ma H, Song X, He L, Ye X, Li X. A meta-analysis of the prognostic significance of Golgi protein 73 in hepatocellular carcinoma in Chinese patients. Archives of Medical Science: AMS. 2020;16(5):1104–10.CrossRefPubMed
16.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA Statement. Revista Esp De Nutricion Humana Y Dietetica. 2014;18(3):172–81.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA Statement. Revista Esp De Nutricion Humana Y Dietetica. 2014;18(3):172–81.CrossRef
17.
go back to reference Sai W, Wang L, Zheng W, Yang J, Pan L, Cai Y, Qiu L, Zhang H, Wu W, Yao D. Abnormal expression of Golgi Protein 73 in clinical values and their role in HBV-Related Hepatocellular Carcinoma diagnosis and prognosis. Hepat Mon. 2015;15(12):e32918.CrossRefPubMedPubMedCentral Sai W, Wang L, Zheng W, Yang J, Pan L, Cai Y, Qiu L, Zhang H, Wu W, Yao D. Abnormal expression of Golgi Protein 73 in clinical values and their role in HBV-Related Hepatocellular Carcinoma diagnosis and prognosis. Hepat Mon. 2015;15(12):e32918.CrossRefPubMedPubMedCentral
18.
go back to reference Ye QH, Zhu WW, Zhang JB, Qin Y, Lu M, Lin GL, Guo L, Zhang B, Lin ZH, Roessler S, et al. GOLM1 modulates EGFR/RTK cell-surface recycling to Drive Hepatocellular Carcinoma Metastasis. Cancer Cell. 2016;30(3):444–58.CrossRefPubMedPubMedCentral Ye QH, Zhu WW, Zhang JB, Qin Y, Lu M, Lin GL, Guo L, Zhang B, Lin ZH, Roessler S, et al. GOLM1 modulates EGFR/RTK cell-surface recycling to Drive Hepatocellular Carcinoma Metastasis. Cancer Cell. 2016;30(3):444–58.CrossRefPubMedPubMedCentral
19.
go back to reference Li Q, Ma Y, Xu W. High GOLPH3 expression is associated with poor prognosis and invasion of hepatocellular carcinoma. Mol Med Rep. 2015;11(6):4315–20.CrossRefPubMed Li Q, Ma Y, Xu W. High GOLPH3 expression is associated with poor prognosis and invasion of hepatocellular carcinoma. Mol Med Rep. 2015;11(6):4315–20.CrossRefPubMed
20.
go back to reference He EY, Wang N, Fan Y. Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery Disease: a metaanalysis of randomized trials. J Vascular Interventional Radiology: JVIR. 2008;19(4):499–503.CrossRef He EY, Wang N, Fan Y. Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery Disease: a metaanalysis of randomized trials. J Vascular Interventional Radiology: JVIR. 2008;19(4):499–503.CrossRef
21.
go back to reference Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, Fimmel CJ. GP73, a novel golgi-localized protein upregulated by viral Infection. Gene. 2000;249(1–2):53–65.CrossRefPubMedPubMedCentral Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, Fimmel CJ. GP73, a novel golgi-localized protein upregulated by viral Infection. Gene. 2000;249(1–2):53–65.CrossRefPubMedPubMedCentral
22.
go back to reference Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral Liver Disease. Hepatology. 2002;35(6):1431–40.CrossRefPubMed Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral Liver Disease. Hepatology. 2002;35(6):1431–40.CrossRefPubMed
23.
go back to reference Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D’Amelio A, Lok AS, Block TM. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43(6):1007–12.CrossRefPubMed Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D’Amelio A, Lok AS, Block TM. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43(6):1007–12.CrossRefPubMed
24.
go back to reference El Shafie MA, Fawzy AM, Abd Al Monem E, Abbass S, Zakaria DM, El Baz S. Golgi Protein 73 (GP73) as a Novel Serum Marker for Early Detection of Hepatocellular Carcinoma in Egyptian patients. Life Sci Journal-Acta Zhengzhou Univ Overseas Ed. 2012;9(2):823–30. El Shafie MA, Fawzy AM, Abd Al Monem E, Abbass S, Zakaria DM, El Baz S. Golgi Protein 73 (GP73) as a Novel Serum Marker for Early Detection of Hepatocellular Carcinoma in Egyptian patients. Life Sci Journal-Acta Zhengzhou Univ Overseas Ed. 2012;9(2):823–30.
25.
go back to reference Gao J. Application of Golgi Protein 73 and Alpha Fetoprotein in Monitoring the Treatment Response of Hepatectomy and Recurrence in Hepatocellular Carcinoma. Med J Wuhan Univ 2013. Gao J. Application of Golgi Protein 73 and Alpha Fetoprotein in Monitoring the Treatment Response of Hepatectomy and Recurrence in Hepatocellular Carcinoma. Med J Wuhan Univ 2013.
26.
go back to reference Wang NY, Wang C, Li W, Wang GJ, Cui GZ, He H, Zhao HJ. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J cancer Prevention: APJCP. 2014;15(4):1539–44.CrossRef Wang NY, Wang C, Li W, Wang GJ, Cui GZ, He H, Zhao HJ. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J cancer Prevention: APJCP. 2014;15(4):1539–44.CrossRef
27.
go back to reference Dong M, Chen ZH, Li X, Li XY, Wen JY, Lin Q, Ma XK, Wei L, Chen J, Ruan DY, et al. Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma. Oncol Lett. 2017;14(5):6277–84.PubMedPubMedCentral Dong M, Chen ZH, Li X, Li XY, Wen JY, Lin Q, Ma XK, Wei L, Chen J, Ruan DY, et al. Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma. Oncol Lett. 2017;14(5):6277–84.PubMedPubMedCentral
28.
go back to reference Li B, Liu A, Wen Y, Yang G, Zhao J, Li X, Mao Y, Li B. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data. J Clin Lab Anal. 2021;35(9):e23932.CrossRefPubMedPubMedCentral Li B, Liu A, Wen Y, Yang G, Zhao J, Li X, Mao Y, Li B. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data. J Clin Lab Anal. 2021;35(9):e23932.CrossRefPubMedPubMedCentral
29.
go back to reference Liang H, Ai-Jun J, Ji-Zong Z, Jian-Bo H, Liang Z, Yong-Xiang Y, Chen Y. Clinicopathological significance of miR-27b targeting Golgi protein 73 in patients with hepatocellular carcinoma. Anticancer Drugs. 2019;30(2):186–94.CrossRefPubMed Liang H, Ai-Jun J, Ji-Zong Z, Jian-Bo H, Liang Z, Yong-Xiang Y, Chen Y. Clinicopathological significance of miR-27b targeting Golgi protein 73 in patients with hepatocellular carcinoma. Anticancer Drugs. 2019;30(2):186–94.CrossRefPubMed
30.
go back to reference Sun Y, Yang H, Mao Y, Xu H, Zhang J, Li G, Lu X, Sang X, Zhao H, Zhong S, et al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with Tumor aggression but not survival. J Gastroenterol Hepatol. 2011;26(7):1207–12.CrossRefPubMed Sun Y, Yang H, Mao Y, Xu H, Zhang J, Li G, Lu X, Sang X, Zhao H, Zhong S, et al. Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with Tumor aggression but not survival. J Gastroenterol Hepatol. 2011;26(7):1207–12.CrossRefPubMed
31.
go back to reference Chen X, Wang Y, Tao J, Shi Y, Gai X, Huang F, Ma Q, Zhou Z, Chen H, Zhang H, et al. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and growth of Xenograft tumors in mice. Gastroenterology. 2015;149(3):741–752e714.CrossRefPubMed Chen X, Wang Y, Tao J, Shi Y, Gai X, Huang F, Ma Q, Zhou Z, Chen H, Zhang H, et al. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and growth of Xenograft tumors in mice. Gastroenterology. 2015;149(3):741–752e714.CrossRefPubMed
32.
go back to reference Shimada K, Sano T, Sakamoto Y, Kosuge T. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer. 2005;104(9):1939–47.CrossRefPubMed Shimada K, Sano T, Sakamoto Y, Kosuge T. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer. 2005;104(9):1939–47.CrossRefPubMed
33.
go back to reference Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Müllhaupt B, et al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology. 2009;49(5):1602–9.CrossRefPubMed Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Müllhaupt B, et al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology. 2009;49(5):1602–9.CrossRefPubMed
Metadata
Title
A meta-analysis of the prognostic impact of tissue golgi protein 73 (tGP73) in hepatocellular carcinoma
Authors
Wei-Ming Yu
Guo-Wei Li
Ming-Geng Lou
Zheng-Yu Wu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-03050-5

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.